Trial Profile
Open-label, Multicenter Study of the 18F-labeled PET/CT (Positron Emission Tomography / Computed Tomography) Tracer BAY86-9596 Following a Single Intravenous Administration of 200 or 300 MBq (Corresponding to ≤ 18 µg Mass Dose) for Evaluation of Radiation Dosimetry, Plasma Pharmacokinetics, Safety and Tolerability in Healthy Volunteers (200 MBq) as Well as Investigation of Safety, Tolerability and Diagnostic Performance in Patients (300 MBq) With Non-small Cell Lung Cancer, Breast Cancer, Head and Neck Cancer and in Patients With Inflammation.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs BAY 869596 (Primary) ; Fludeoxyglucose F-18
- Indications Breast cancer; Head and neck cancer; Inflammation; Non-small cell lung cancer; Squamous cell cancer
- Focus Diagnostic use
- Sponsors Life Molecular Imaging; Piramal Imaging
- 27 Mar 2019 According to a Life Molecular Imaging, Piramal imaging changed its name to Life Molecular Imaging.
- 14 Nov 2014 New trial record